Fireside Chat: Why Is PIMS Critical to Ensuring IDBS Can Help BioPharma Bring Life-changing Therapies to Market Faster?

Bob Di Scipio, Former CEO, Skyland Analytics
Christian Marcazzo, General Manager, IDBS

See all i3 2022 Sessions

About the Session:

Don’t miss this session where IDBS’ General Manager, Christian Marcazzo, sits down with Bob Di Scipio, Founder and CEO of recently acquired Skyland Analytics, to share insights on their respective mission to help the BioPharma industry reduce the time, cost and risk of bringing new therapies to market.

You’ll learn about the market dynamics that led each organization to develop new innovative data management technology and the increasingly important role technology plays in today’s disparate manufacturing networks. Christian and Bob will discuss the key factors and expectations of bringing IDBS’ Polar and Skyland PIMS solutions together and the ultimate of establishing an end-to-end BioPharma Lifecycle Management (BPLM) offering.

Watch the Session

You may also like these sessions:

See all i3 2022 Sessions
Bob Di Scipio

Bob has spent 25 years serving the life science sector in management and legal roles. Most recently, he served as CEO of Skyland Analytics which developed PIMS™ the first Part 11 compliant, cloud-based application for drug manufacturing data management and supply chain transparency. Prior to Skyland, he served as CEO of Aegis Analytical Corporation (acquired by Dassault Systemes), which developed the BIOVIA Discoverant manufacturing informatics software for the life science sector. Bob has also served in legal and management positions with Martek Biosciences and OmegaTech, and as a tax attorney with PWC.

Christian Marcazzo

Christian Marcazzo has been the General Manager of IDBS since 2018, leading the business through a period of transition, investment and growth as a Danaher Operating Company. Prior to joining IDBS, Christian has spent 25 years at the interface of biology and software, leading organizations like Perkin Elmer, Spotfire and LION bioscience through the genomics revolution and the digitization of R&D. He has a BA in Molecular and Cell Biology from the University of California, Berkeley and is based at the IDBS headquarters in Surrey, UK.